These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 21742097)

  • 1. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials.
    Berger JS; Lala A; Krantz MJ; Baker GS; Hiatt WR
    Am Heart J; 2011 Jul; 162(1):115-24.e2. PubMed ID: 21742097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin for primary prevention of cardiovascular disease events.
    Nemerovski CW; Salinitri FD; Morbitzer KA; Moser LR
    Pharmacotherapy; 2012 Nov; 32(11):1020-35. PubMed ID: 23019080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Primary prevention of cardiovascular diseases with acetylsalicylic acid].
    Waltering A; Hemkens L; Florack C
    Dtsch Med Wochenschr; 2005 Dec; 130(49):2847-52. PubMed ID: 16317615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Aspirin in cardiovascular prevention: does the approach differ by gender?].
    Temizhan A
    Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():2-4. PubMed ID: 18160359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us?
    Krane V; Wanner C
    Am J Kidney Dis; 2005 Mar; 45(3):607-9. PubMed ID: 15754285
    [No Abstract]   [Full Text] [Related]  

  • 8. Aspirin and primary cardiovascular prevention. Uncertain balance between benefits and risks.
    Prescrire Int; 2010 Nov; 19(110):258-61. PubMed ID: 21284360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin in the primary prevention of cardiovascular disease.
    Galloway CF; Stevenson JC
    Maturitas; 2011 Jan; 68(1):3-4. PubMed ID: 21111550
    [No Abstract]   [Full Text] [Related]  

  • 10. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on aspirin. People with heart disease should take aspirin; the decision is trickier for those without it.
    Harv Heart Lett; 2011 Aug; 21(12):3. PubMed ID: 21991607
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events.
    Rodondi N; Bauer DC
    Am J Med; 2004 Oct; 117(7):528-30. PubMed ID: 15464713
    [No Abstract]   [Full Text] [Related]  

  • 13. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
    Morimoto T; Fukui T; Lee TH; Matsui K
    Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
    Spinler SA
    Pharmacotherapy; 2009 Jul; 29(7):812-21. PubMed ID: 19558255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
    Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
    Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale.
    U.S. Preventive Services Task Force
    Am Fam Physician; 2002 May; 65(10):2107-10. PubMed ID: 12046780
    [No Abstract]   [Full Text] [Related]  

  • 18. Aspirin in the secondary prevention of cardiovascular disease: an update of the APTC meta-analysis.
    Lièvre M; Cucherat M
    Fundam Clin Pharmacol; 2010 Jun; 24(3):385-91. PubMed ID: 19678849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin for the prevention of cardiovascular morbidity.
    Sanchez-Ross M; Waller AH; Maher J; Klapholz M; Haider B; Kaluski E
    Minerva Med; 2010 Aug; 101(4):205-14. PubMed ID: 21030934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
    Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
    Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.